AI firm OpenAI is introducing an early version of a new AI model called GPT-Rosalind that is designed to help speed up drug discovery and scientific research. The model focuses on life sciences and is meant to help researchers analyze large amounts of data and turn scientific findings into real-world healthcare applications. Notably, it will first be released as a limited research preview to select business customers, which include companies like Amgen (AMGN) and Moderna (MRNA).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
It is worth noting that this move is part of a trend across the tech industry. Companies like Anthropic and Alphabet (GOOGL) are also pushing into healthcare and scientific research using AI. For example, Google DeepMind has already made progress in this area, with its AlphaFold system helping to predict protein structures and even contributing to a Nobel Prize in Chemistry. Because of this, AI is increasingly seen as a promising tool for advancing science, as some AI-assisted drugs have already reached early clinical trials.
However, OpenAI also admits that AI is not yet capable of independently creating new treatments. At the same time, safety remains a key concern, as more powerful models raise risks, such as the possibility of creating biological weapons. To address this, OpenAI has built in safeguards, including systems that flag potentially dangerous activity and limits on how the model can be used.
Are GOOGL Shares a Good Buy?
Turning to Wall Street, analysts have a Strong Buy consensus rating on GOOGL stock based on 26 Buys and five Holds assigned in the past three months. Furthermore, the average GOOGL price target of $385.97 per share implies 15.1% upside potential.
